Rowan Chapman
Entrepreneur, Investor, Board Member
San Francisco Bay Area
Invests in
Sectors:
Locations:
Min Investment:
$0.00Max Investment:
$0.00Target Investment:
$0.00
Skills
Education
Lists including Rowan
Work Experience
2023
Adjunct Lecturer, BioEngineering
2023
Non Executive Director
2022
A leading venture investor in Cambridge backing and building category-leading deep tech and life sciences companies.
2023
Co-Founder
2023
Investing in early stage companies at the intersection of science, engineering, and computation.
2023
Board Member
2023
Building a completely new way to quickly structure, standardize, and clean healthcare and clinical data using AI.
2021
Board Member
2021
An automated platform to enable a richer understanding of individual cell behaviors, interactions, and functions across a range of stimuli and parameters, at massively parallel scale.
2019
Board Member (NTRA)
2019
Committees: Chair Compensation, Member Audit Natera® is a worldwide genetic testing and diagnostics company that’s changing how doctors and patients manage genetic disease. Our team includes clinicians, scientists, biostatisticians, researchers, and talented laboratory professionals from around the globe.
2020
Co-Founder, Advisor
2020
Initiate partners with entrepreneurs to launch innovative companies built on bold ideas. We focus at the intersections of healthcare, life sciences and technology. Founder success is our success.
2014 - 2024
Board Member
2014 - 2024
Independent board member Committees: Chair Compensation, Member Audit Evidation Health seeks to improve health outcomes through clinically and economically beneficial digital health solutions and new approaches to predictive analytics.
2017 - 2019
Senior VP, Head of Innovation, Western North America, Australia & New Zealand
2017 - 2019
Led the J&J California team responsible for entrepreneurial ecosystem collaborations, deals and investments across Pharmaceutical, Medical Device and Consumer sectors. Drove deal structures including co-development, licensing, sponsored research and investment with negotiated terms ranging to >$1B.
2015 - 2018
Board Member
2015 - 2018
Initially CEO, then board member. Acquired by Thorne (THRN) Drawbridge Health is focused on enabling personal diagnostic testing – anytime, anywhere with a people-friendly system for collecting and stabilizing blood samples